- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Submit a Manuscript
- Table of Contents
Volume 2013 (2013), Article ID 918207, 8 pages
Beyond the Limits of Oxygen: Effects of Hypoxia in a Hormone-Independent Prostate Cancer Cell Line
1Biophysics Unit, Institute of Biomedical Research on Light and Image (IBILI), Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, Celas, 3000-548 Coimbra, Portugal
2CICS-UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal
3Centre of Investigation on Environment, Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra, Coimbra, Portugal
4Faculty of Sciences and Technology, University of Coimbra, Coimbra, Portugal
5Applied Molecular Biology and Hematology Group, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
Received 24 June 2013; Accepted 13 August 2013
Academic Editors: Y. Akiyama, W. Kildal, and L. Mutti
Copyright © 2013 A. C. Mamede et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- M. M. Center, A. Jemal, J. Lortet-Tieulent et al., “International variation in prostate cancer incidence and mortality rates,” European Urology, vol. 61, no. 6, pp. 1079–1092, 2012.
- A. Leibovitz, Y. Baumoehl, and R. Segal, “Increased incidence of pathological and clinical prostate cancer with age: age related alterations of local immune surveillance,” Journal of Urology, vol. 172, no. 2, pp. 435–437, 2004.
- R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012.
- O. Cussenot, A. Valeri, P. Berthon, G. Fournier, and P. Mangin, “Hereditary prostate cancer and other genetic predispositions to prostate cancer,” Urologia Internationalis, vol. 60, no. 2, pp. 30–34, 1998.
- C. A. Heinlein and C. Chang, “Androgen receptor in prostate cancer,” Endocrine Reviews, vol. 25, no. 2, pp. 276–308, 2004.
- K. J. Pienta and P. S. Esper, “Risk factors for prostate cancer,” Annals of Internal Medicine, vol. 118, no. 10, pp. 793–803, 1993.
- I. Papandreou, C. Krishna, F. Kaper, D. Cai, A. J. Giaccia, and N. C. Denko, “Anoxia is necessary for tumor cell toxicity caused by a low-oxygen environment,” Cancer Research, vol. 65, no. 8, pp. 3171–3178, 2005.
- N. Chan, M. Milosevic, and R. G. Bristow, “Tumor hypoxia, DNA repair and prostate cancer regression: new targets and new therapies,” Future Oncology, vol. 3, no. 3, pp. 329–341, 2007.
- A. M. Abrantes, M. E. Serra, D. Murtinho, A. R. Gonsalves, and M. F. Botelho, “An insight into tumoral hypoxia: the radiomarkers and clinical applications,” Oncology Reviews, vol. 3, no. 1, pp. 3–18, 2009.
- A. M. Abrantes, E. Serra, C. Gonçalves et al., “Tumour hypoxia and technetium tracers: in vivo studies,” Current Radiopharmaceuticals, vol. 5, no. 2, pp. 99–105, 2012.
- G. D. Stewart, J. A. Ross, D. B. McLaren, C. C. Parker, F. K. Habib, and A. C. P. Riddick, “The relevance of a hypoxic tumour microenvironment in prostate cancer,” BJU International, vol. 105, no. 1, pp. 8–13, 2010.
- M. Höckel and P. Vaupel, “Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects,” Journal of the National Cancer Institute, vol. 93, no. 4, pp. 266–276, 2001.
- A. C. Mamede, A. S. Pires, A. M. Abrantes, et al., “Cytotoxicity of ascorbic acid in a human colorectal adenocarcinoma cell line (WiDr): in vitro and in vivo studies,” Nutrition and Cancer, vol. 64, pp. 1049–1057, 2012.
- A. M. Abrantes, M. E. S. Serra, A. C. Gonçalves et al., “Hypoxia-induced redox alterations and their correlation with 99mTc-MIBI and 99mTc-HL-91 uptake in colon cancer cells,” Nuclear Medicine and Biology, vol. 37, no. 2, pp. 125–132, 2010.
- P. Houghton, R. Fang, I. Techatanawat, G. Steventon, P. J. Hylands, and C. C. Lee, “The sulphorhodamine (SRB) assay and other approaches to testing plant extracts and derived compounds for activities related to reputed anticancer activity,” Methods, vol. 42, no. 4, pp. 377–387, 2007.
- C. Liang, A. Y. Park, and J. Guan, “In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro,” Nature Protocols, vol. 2, no. 2, pp. 329–333, 2007.
- A. F. Santos, H. Huang, and D. J. Tindall, “The androgen receptor: a potential target for therapy of prostate cancer,” Steroids, vol. 69, no. 2, pp. 79–85, 2004.
- T. Gilligan and P. W. Kantoff, “Chemotherapy for prostate cancer,” Urology, vol. 60, no. 3, pp. 94–100, 2002.
- D. J. Smith, M. Jaggi, W. Zhang et al., “Metallothioneins and resistance to cisplatin and radiation in prostate cancer,” Urology, vol. 67, no. 6, pp. 1341–1347, 2006.
- T. Wakasugi, H. Izumi, T. Uchiumi et al., “ZNF143 interacts with p73 and is involved in cisplatin resistance through the transcriptional regulation of DNA repair genes,” Oncogene, vol. 26, no. 36, pp. 5194–5203, 2007.
- M. P. Wirth, O. W. Hakenberg, and M. Froehner, “Antiandrogens in the treatment of prostate Cancer,” European Urology, vol. 51, no. 2, pp. 306–314, 2007.
- L. Montalvo, M. J. Carmena, O. Bolaños, N. Rodríguez-Henche, M. Sánchez-Chapado, and J. C. Prieto, “Effects of the antiandrogen flutamide on the expression of protein kinase C isoenzymes in LNCaP and PC3 human prostate cancer cells,” Bioscience Reports, vol. 24, no. 1, pp. 11–21, 2004.
- F. Al-Saeedi, “Effects of flutamide on [Methyl-3H]-Choline uptake in human prostate Cancer-3 cells: A Pilot Study,” Current Therapeutic Research, vol. 68, no. 4, pp. 226–241, 2007.
- J. A. Watson, C. J. Watson, A. McCrohan et al., “Generation of an epigenetic signature by chronic hypoxia in prostate cells,” Human molecular genetics, vol. 18, no. 19, pp. 3594–3604, 2009.
- L. J. Frederiksen, D. R. Siemens, J. P. Heaton, L. R. Maxwell, M. A. Adams, and C. H. Graham, “Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate,” Journal of Urology, vol. 170, no. 3, pp. 1003–1007, 2003.
- N. Chen, X. Chen, R. Huang et al., “BCL-xL is a target gene regulated by hypoxia-inducible factor-1α,” The Journal of Biological Chemistry, vol. 284, no. 15, pp. 10004–10012, 2009.
- L. Marignol, M. Coffey, M. Lawler, and D. Hollywood, “Hypoxia in prostate cancer: a powerful shield against tumour destruction?” Cancer Treatment Reviews, vol. 34, no. 4, pp. 313–327, 2008.
- Y. Dai, K. Bae, and D. W. Siemann, “Impact of hypoxia on the metastatic potential of human prostate cancer Cells,” International Journal of Radiation Oncology Biology Physics, vol. 81, no. 2, pp. 521–528, 2011.
- X. Xu, M. Mikhailova, Z. Chen et al., “Peptide from the C-terminal domain of tissue inhibitor of matrix metalloproteinases-2 (TIMP-2) inhibits membrane activation of matrix metalloproteinase-2 (MMP-2),” Matrix Biology, vol. 30, no. 7-8, pp. 404–412, 2011.
- L. Yu and C. A. Hales, “Long-term exposure to hypoxia inhibits tumor progression of lung cancer in rats and mice,” BMC Cancer, vol. 11, article 331, 2011.